Clearly inferior treatments are unethical. Donald Berry at MD Anderson in Houston TX and Jay Kadane at Carnegie Mellon have been working on more ethical designs within the Bayesian framework. In particular, response adaptive designs reduce the assignment to and continuation of patients on inferior treatments.
Bert Gunter <gunter.ber...@gene.com> Sent by: r-help-boun...@r-project.org 09/20/2010 01:31 PM To r-help@r-project.org cc Subject [R] OT: Is randomization for targeted cancer therapies ethical? Hi Folks: **Off Topic** Those interested in clinical trials may find the following of interest: http://www.nytimes.com/2010/09/19/health/research/19trial.html It concerns the ethicality of randomizing those with life-threatening disease to relatively ineffective SOC when new "biologically targeted" therapies "appear" to be more effective. While the context may be new, the debate, itself, is not: Tukey wrote (or maybe it was talked -- I can't remember for sure) about this about 30 years ago. I'm sure many other also have done so. Cheers, Bert -- Bert Gunter Genentech Nonclinical Biostatistics ______________________________________________ R-help@r-project.org mailing list https://stat.ethz.ch/mailman/listinfo/r-help PLEASE do read the posting guide http://www.R-project.org/posting-guide.html and provide commented, minimal, self-contained, reproducible code. [[alternative HTML version deleted]] ______________________________________________ R-help@r-project.org mailing list https://stat.ethz.ch/mailman/listinfo/r-help PLEASE do read the posting guide http://www.R-project.org/posting-guide.html and provide commented, minimal, self-contained, reproducible code.
